Table 7.

Effect-to-treatment analysis: 15% attenuation model estimation

No	Study	MAST	p Value	PNC	CEST	CENC	METR	EER	p Value	CNTM
										1	2	3	4	5	6	7
1	Brandes153	10.15 (9.24–11.06)	0.943	6	9.64	4	1.20 (0.74–1.95)	1.01	0.979	∞	2.56	1.59	0.99	1.65	1.59	91
2	Strik155	8.40 (7.52–9.29)	0.015	6	7.98	4	0.81 (0.44–1.48)	0.68	0.302	−2.56	∞	4.22	1.62	4.63	4.19	−2.64
3	Abacioglu156	7.34 (6.46–8.22)	<0.001	6	6.98	4	0.57 (0.37–0.89)	0.48	0.016	−1.59	−4.22	∞	2.62	−47.9	592	−1.62
4	Berrocal157	5.63 (4.76–6.51)	<0.001	6	5.35	3	0.19 (0.08–0.49)	0.16	<0.001	−0.99	−1.62	−2.62	∞	−2.48	−2.63	−1.00
5	WA (1–4)	7.44 (6.56–8.31)	<0.001	6	7.07	4	0.59 (0.40–0.88)	0.50	0.015	−1.65	−4.63	47.9	2.48	∞	44.3	−1.68
6	WA (2–4)*	7.34 (6.46–8.21)	<0.001	6	6.97	4	0.57 (0.39–0.85)	0.48	0.011	−1.59	−4.19	−592	2.63	−44.3	∞	−1.62
7	Sahinbas23	10.10 (9.10–11.10)	1.000	6	9.5	4	1.19 (0.59–2.40)	1.00	1.000	−91	2.64	1.62	1.00	1.68	1.62	∞

*Main comparator.

CA, coefficient of attenuation; CENC, cost-effective number of cycles; CEST, cost-effective survival time; EER, effect enhancement rate; MAST, maximal attainable survival time; METR, median effect-to-treatment ratio; WA, weighted average; PNC, peak number of cycles.